KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EBT (2016 - 2025)

Historic EBT for Sarepta Therapeutics (SRPT) over the last 14 years, with Q2 2025 value amounting to $153.6 million.

  • Sarepta Therapeutics' EBT rose 103160.49% to $153.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $373.0 million, marking a year-over-year increase of 49940.86%. This contributed to the annual value of $260.8 million for FY2024, which is 15013.94% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported EBT of $153.6 million as of Q2 2025, which was up 103160.49% from $171.7 million recorded in Q4 2024.
  • Sarepta Therapeutics' 5-year EBT high stood at $171.7 million for Q4 2024, and its period low was -$512.7 million during Q1 2023.
  • Over the past 5 years, Sarepta Therapeutics' median EBT value was -$47.9 million (recorded in 2021), while the average stood at -$71.4 million.
  • Its EBT has fluctuated over the past 5 years, first plummeted by 86330.21% in 2021, then soared by 103160.49% in 2025.
  • Over the past 5 years, Sarepta Therapeutics' EBT (Quarter) stood at -$121.9 million in 2021, then increased by 16.89% to -$101.3 million in 2022, then surged by 139.85% to $40.4 million in 2023, then skyrocketed by 325.41% to $171.7 million in 2024, then fell by 10.54% to $153.6 million in 2025.
  • Its EBT was $153.6 million in Q2 2025, compared to $171.7 million in Q4 2024 and $34.0 million in Q3 2024.